The company said its products are also informing surgery and treatment decision-making using the same minimally invasive patient sample, according to a statement.
"Our RNA platform uniquely enables our Afirma offering to answer important clinical questions that can guide various points in a patient's journey, helping to improve outcomes," CEO Bonnie Anderson said. "Further, by providing this comprehensive information from the original biopsy used in diagnosis, we can streamline workflows and enable patients to get the answers they need faster and more easily."
Shares rose by more than 3% intraday.
Price: 28.42, Change: +0.85, Percent Change: +3.10
|Analysts' Decrease 2019, 2020 Consensus Estimates fo...|
|2019, 2020, and Q2 Earnings Estimates for Exxon Mobi...|
|2019 Estimate for YIT Oyj Scaled Up but 2020 Earning...|
|Watsco's 2019, 2020, and Q3 Earnings Estimates Reduced|
|Westlake Chemical's Q2, 2019, and 2020 Earnings Redu...|